Document Detail


Laquinimod in multiple sclerosis.
MedLine Citation:
PMID:  21450529     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Laquinimod is a novel, orally administered immune-modulatory molecule in advanced phase clinical trials in relapsing-remitting multiple sclerosis. Experimental evidence to date, derived mostly from animal models of multiple sclerosis, suggests that laquinimod may mediate its effects via modulating pro-inflammatory immune responses and interfering with cell trafficking, as well as potentially acting directly in the central nervous system to limit demyelination and axonal injury. The clinical trial results to date have established efficacy on imaging markers of disease activity and have shown a favorable safety and tolerability profile. If phase III studies confirm clinical efficacy and safety, laquinimod would represent a welcome new option in the treatment of multiple sclerosis.
Authors:
Paul S Giacomini; Amit Bar-Or
Related Documents :
13130479 - Systemic sclerosis th2 cells inhibit collagen production by dermal fibroblasts via memb...
19122799 - Heterogeneity in the cd4 t cell compartment and the variability of neonatal immune resp...
14607909 - Intracellular thiols contribute to th2 function via a positive role in il-4 production.
10614729 - Deviation of the allergic ige to an igg response by gene immunotherapy.
11516529 - Factors that modify penicillamine-induced autoimmunity in brown norway rats: failure of...
18383559 - Type 1 diabetes: can exercise impair the autoimmune event? the l-arginine/glutamine cou...
19915659 - Nitric oxide releasing nanoparticles are therapeutic for staphylococcus aureus abscesse...
7806909 - Genetic determinants of mortality in acute necrotizing pancreatitis.
14507339 - Caspase-dependent and caspase-independent signalling of apoptosis in the penumbra follo...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-4
Journal Detail:
Title:  Clinical immunology (Orlando, Fla.)     Volume:  -     ISSN:  1521-7035     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883537     Medline TA:  Clin Immunol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Affiliation:
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada; Multiple Sclerosis Clinic, Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome.
Next Document:  Potential neuroprotective effects of continuous topiramate therapy in the developing brain.